These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 8442909)

  • 1. Anti-CD4 antibodies generated in response to HIV-1 rgp160 immunization of HIV-1-infected chimpanzees.
    Keiser P; Fernie B; Tacket C; Wecksler W; Keay S
    AIDS; 1993 Jan; 7(1):136-8. PubMed ID: 8442909
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunization of chimpanzees with recombinant gp160, but not infection with human immunodeficiency virus type 1, induces envelope-specific Th1 memory cells.
    Mannhalter JW; Fischer MB; Wolf HM; Küpcü Z; Barrett N; Dorner F; Eder G; Eibl MM
    J Infect Dis; 1995 Feb; 171(2):437-40. PubMed ID: 7844384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-CD4 anti-idiotype antibodies in volunteers immunized with rgp160 of HIV-1 or infected with HIV-1.
    Keay S; Tacket CO; Murphy JR; Handwerger BS
    AIDS Res Hum Retroviruses; 1992 Jun; 8(6):1091-8. PubMed ID: 1503823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.
    Dis Markers; 1991; 9(1):51. PubMed ID: 1742945
    [No Abstract]   [Full Text] [Related]  

  • 5. Characterization of a vaccinia-derived recombinant HIV-1 gp160 candidate vaccine and its immunogenicity in chimpanzees.
    Barrett N; Eder G; Dorner F
    Biotechnol Ther; 1991; 2(1-2):91-106. PubMed ID: 1845126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.
    Berman PW; Gregory TJ; Riddle L; Nakamura GR; Champe MA; Porter JP; Wurm FM; Hershberg RD; Cobb EK; Eichberg JW
    Nature; 1990 Jun; 345(6276):622-5. PubMed ID: 2190095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improbability of harmful autoimmune responses resulting from immunization with HIV-1 envelope glycoproteins.
    Neurath AR; Strick N; Li YY; Jiang S
    AIDS Res Hum Retroviruses; 1993 Dec; 9(12):1195-208. PubMed ID: 8142138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of nonprotective vaccination on antibody response to subsequent human immunodeficiency virus infection.
    Pincus SH; Messer KG; Hu SL
    J Clin Invest; 1994 Jan; 93(1):140-6. PubMed ID: 8282780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic peptides define the fine specificity of the human immunodeficiency virus (HIV) gp160 humoral immune response in HIV type 1-infected chimpanzees.
    Warren RQ; Wolf H; Shuler KR; Eichberg JW; Zajac RA; Boswell RN; Kanda P; Kennedy RC
    J Virol; 1990 Feb; 64(2):486-92. PubMed ID: 2404138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunization of chimpanzees with the HIV-1 glycoprotein gp160 induces long-lasting T-cell memory.
    Mannhalter JW; Pum M; Wolf HM; Küpcü Z; Barrett N; Dorner F; Eder G; Eibl MM
    AIDS Res Hum Retroviruses; 1991 May; 7(5):485-93. PubMed ID: 1714748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network.
    Graham BS; Matthews TJ; Belshe RB; Clements ML; Dolin R; Wright PF; Gorse GJ; Schwartz DH; Keefer MC; Bolognesi DP
    J Infect Dis; 1993 Mar; 167(3):533-7. PubMed ID: 8095059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160.
    Kovacs JA; Vasudevachari MB; Easter M; Davey RT; Falloon J; Polis MA; Metcalf JA; Salzman N; Baseler M; Smith GE
    J Clin Invest; 1993 Aug; 92(2):919-28. PubMed ID: 7688766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autoreactivity in HIV-infected individuals does not increase during vaccination with envelope rgp160.
    Lundholm P; Wahren M; Sandström E; Volvovitz F; Wahren B
    Immunol Lett; 1994 Jul; 41(2-3):147-53. PubMed ID: 8002030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Production of long-lived neutralizing antibodies to HIV-1 IIIB in mice with a vaccinia recombinant virus-infected cell vaccine expressing gp160.
    Parry C; McLain L; Dimmock NJ
    AIDS Res Hum Retroviruses; 1994 Feb; 10(2):205-12. PubMed ID: 8198873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epitope mapping and topology of baculovirus-expressed HIV-1 gp160 determined with a panel of murine monoclonal antibodies.
    Abacioglu YH; Fouts TR; Laman JD; Claassen E; Pincus SH; Moore JP; Roby CA; Kamin-Lewis R; Lewis GK
    AIDS Res Hum Retroviruses; 1994 Apr; 10(4):371-81. PubMed ID: 8068416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. Clin Exp Immun 1994;98:178-84.
    DePalma L
    Pediatr AIDS HIV Infect; 1995 Apr; 6(2):97-8. PubMed ID: 11361387
    [No Abstract]   [Full Text] [Related]  

  • 17. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein.
    Cooney EL; McElrath MJ; Corey L; Hu SL; Collier AC; Arditti D; Hoffman M; Coombs RW; Smith GE; Greenberg PD
    Proc Natl Acad Sci U S A; 1993 Mar; 90(5):1882-6. PubMed ID: 8446603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160.
    Mosier DE; Gulizia RJ; MacIsaac PD; Corey L; Greenberg PD
    Proc Natl Acad Sci U S A; 1993 Mar; 90(6):2443-7. PubMed ID: 8460155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of serum antibody responses to recombinant HIV-1 gp160 vaccine by enzyme immunoassay. NIAID AIDS Vaccine Clinical Trials Network.
    Viscidi R; Ellerbeck E; Garrison L; Midthun K; Clements ML; Clayman B; Fernie B; Smith G
    AIDS Res Hum Retroviruses; 1990 Nov; 6(11):1251-6. PubMed ID: 1706607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunization with subunit human immunodeficiency virus vaccine generates stronger T helper cell immunity than natural infection.
    Clerici M; Tacket CO; Via CS; Lucey DR; Muluk SC; Zajac RA; Boswell RN; Berzofsky JA; Shearer GM
    Eur J Immunol; 1991 Jun; 21(6):1345-9. PubMed ID: 1845391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.